Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Anticancer Drugs ; 33(1): e802-e807, 2022 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-34459464

RESUMEN

The incidence of lung cancer is increasing yearly worldwide, and targeted medicines are the main choice for lung cancer patients. However, there has been no relevant research about the analysis and adjustment of drug combinations for cancer patients with hypertension and hyperlipidemia until now. Here, we reported a case of medicine adjustment for a patient of lung cancer with hypertension and hyperlipidemia. The patient was diagnosed as right lung adenocarcinoma with lymph node metastasis and continued taking gefitinib tablets to maintain therapeutic efficacy after the end of chemotherapy. Severe paronychia and a high plasma concentration of gefitinib were noticed when the patient visited the hospital for reexamination. The clinical pharmacist found that the patient took nifedipine sustained-release tablets and simvastatin tablets simultaneously, and these medicines were all substrates of CYP3A4. The clinical pharmacist suggested replacing the medicines for hypertension and hyperlipidemia with valsartan capsules (Diovan) and rosuvastatin calcium tablets (Crestor), respectively. The adverse cutaneous reactions were greatly relieved, and the plasma concentration of gefitinib was decreased when another reexamination was performed. Therapeutic drug monitoring was an important method in our case and provided valuable information to develop individualized treatment strategies. For cancer patients suffering from other diseases such as hypertension and hyperlipidemia, it is necessary to pay special attention to the drug-drug interactions and metabolic pathways among drug combinations.


Asunto(s)
Adenocarcinoma del Pulmón/tratamiento farmacológico , Antihipertensivos/farmacocinética , Antineoplásicos/uso terapéutico , Gefitinib/uso terapéutico , Hipolipemiantes/farmacocinética , Neoplasias Pulmonares/tratamiento farmacológico , Adenocarcinoma del Pulmón/complicaciones , Adenocarcinoma del Pulmón/patología , Antihipertensivos/administración & dosificación , Antihipertensivos/uso terapéutico , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacocinética , Citocromo P-450 CYP3A/metabolismo , Erupciones por Medicamentos , Femenino , Gefitinib/administración & dosificación , Gefitinib/farmacocinética , Humanos , Hiperlipidemias/complicaciones , Hiperlipidemias/tratamiento farmacológico , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Hipolipemiantes/administración & dosificación , Hipolipemiantes/uso terapéutico , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/patología , Metástasis Linfática , Persona de Mediana Edad
2.
Chin Med J (Engl) ; 126(9): 1647-53, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23652045

RESUMEN

BACKGROUND: The effects of triterpenic acid from Prunella vulgaris L. (TAP) on diabetes and its mechanism are uncertain. The aim of this study was to investigate the effects of TAP on antihyperglycemic, antioxidant, and pancreas-protective in streptozotozin (STZ)-diabetic rats. METHODS: The diabetic model was produced by injection of 60 mg/kg STZ. Blood was drawn from the tail vein of rats after 72 hours. Rats with blood glucose ≥ 16.7 mmol/L were considered diabetic. Diabetic rats were randomly divided into four groups: (1) Diabetes rat (STZ), (2) Diabetic rats treated with 50 mg/kg of triterpenic acid from Prunella vulgaris L (STZ + TAP50), (3) Diabetic rats treated with 100 mg/kg TAP (STZ + TAP100), and (4) Diabetic rats treated with 200 mg/kg TAP (STZ + TAP200). Normal rats (n = 10) acted as the control group (NC). TAP was administered by the intragastric route once each day for six weeks. Body weight and the concentration of blood glucose (BG) were measured after three and six weeks. Fructosamine (FMN), malondialdehyde (MDA), and nitric oxide (NO), and the activities of nitric oxide synthase (NOS) and superoxide dismutase (SOD) in serum were determined after six weeks using commercially available kits following the manufacturer's instructions. Pathologic changes in pancreatic ß-cells were also investigated by microscopic examination after hematoxylin-eosin (HE) staining. The level of SOD mRNA in pancreatic ß-cells was measured by polymerase chain reaction (PCR). RESULTS: The levels of BG, FMN, NO, and MDA and the activities of NOS in serum in the four diabetes groups were significantly increased compared with the control group (P < 0.01). The activity of SOD in serum and the body weight was significantly decreased compared with the control group (P < 0.01). After administration of TAP to diabetic rats for six weeks, the body weight and the levels of BG, FMN, MDA, NO and the activity of NOS in serum decreased significantly compared with the STZ group in a dose-dependent manner. The activity of SOD in serum and body weight increased significantly compared with the STZ group in a dose-dependent manner. In addition, diabetic rats showed a significant decrease in SOD mRNA expression in pancreatic ß cells. However, these changes were reversed by TAP. Histopathological examination also showed the protective effect of TAP on pancreatic ß cells. CONCLUSIONS: Triterpenic acid from Prunella vulgaris L. has an anti-diabetic effect, by controlling blood glucose and antioxidants, and has a protective effect on the pancreas.


Asunto(s)
Glucemia/análisis , Diabetes Mellitus Experimental/tratamiento farmacológico , Células Secretoras de Insulina/efectos de los fármacos , Prunella/química , Triterpenos/uso terapéutico , Animales , Diabetes Mellitus Experimental/metabolismo , Células Secretoras de Insulina/patología , Masculino , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Estreptozocina , Superóxido Dismutasa/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA